Microbot Medical Inc. is awaiting a marketing clearance decision from the FDA, and the Israel Innovation Authority has provided non-dilutive grant funding.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Microbot Medical Inc. is awaiting a marketing clearance decision from the FDA, and the Israel Innovation Authority has provided non-dilutive grant funding.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Israel Innovation Authority
support and investment arm of the Israeli government
Nothing else this week.
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA approval enables commercial availability for a product associated with Indianapolis.
- FDA policy proposal affects the operations of AI, Inc.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- FDA approval expands patient access to therapies for ACCORD.
Coverage
Newest first; wire copies grouped- GlobeNewswireMicrobot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities Strengthens Balance Sheet and Continues Commercialization Readiness Plans for the LIBERTY® System as it Nears FDA Mar